Serum dihydroxyacetone kinase peptide m/z 520.3 as predictor of disease severity in patients with compensated chronic hepatitis B

BACKGROUND & AIM: Due to known limitations of liver biopsy, reliable non-invasive serum biomarkers for chronic liver diseases are needed. We performed serum peptidomics for such investigation in compensated chronic hepatitis B (CHB) patients. METHODS: Liquid chromatography combined with tandem m...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Xu, Ming-Yi, Jia, Xiao-Fang, Qu, Ying, Zheng, Rui-Dan, Yuan, Zheng-Hong, Weng, Hong-Lei, Dooley, Steven, Wang, Xing-Peng, Zhang, Li-Jun, Lu, Lun-Gen
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2013
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3851457/
https://ncbi.nlm.nih.gov/pubmed/24289155
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-11-234
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items